ArticleBMC cancer2025
Cathepsin C correlates with M2 macrophage infiltration and regulates the tumor growth and metastasis in non-small cell lung cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cathepsins as Core Players in Obesity Pathogenesis: Emerging Therapeutic Targets.Biomolecules · 2026Review
- A pan-cancer analysis of CTSC as a candidate prognostic and immune-related biomarker.Discover oncology · 2025Article
- Traditional Chinese medicine in the prevention and treatment of lung cancer metastasis by regulating tumor-associated macrophages: a narrative review.Translational lung cancer research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Cathepsin C (CTSC) is a cysteine protease in lysosomes that controls immunological responses. Upregulation CTSC expression was reportedly related with tumor progression and metastasis. The roles and mechanisms of CTSC in non-small cell lung cancer (NSCLC) are still unclear. Through systematic analysis, we found that the level of CTSC was higher in NSCLC and it was correlated with the overall survival (OS) of NSCLC patients. Furthermore, single-cell sequencing (scRNA-seq) analysis suggested that the vast majority of CTSC was expressed in epithelial cell, NK cell, M1 and M2 macrophages, and neutrophil. Gene set enrichment analysis (GSEA) demonstrated the involvement of CTSC in the immune responses and ssGSEA, CIBERSORT-abs, QUANTISEQ, XCELL algorithms results showed CTSC was positively associated with the M2 macrophages infiltration. Besides, CTSC was significantly co-expressed with M2 macrophage maker genes (CD68, CD163), and immune checkpoints. Then, CTSC, CD68, CD163 expression levels were detected by immunohistochemistry in our clinical NSCLC cohort. Subsequently, the regulatory roles of CTSC in the progression and metastasis of NSCLC were investigated both in vitro and in vivo. Our results indicated that knocking down CTSC in NSCLC cell lines restrained cell proliferation and migration. CTSC overexpression in NSCLC cells showed the opposite effects. Targeting CTSC may provide a promising treatment strategy for NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.